Page last updated: 2024-10-20

uracil and Neutropenia

uracil has been researched along with Neutropenia in 31 studies

2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder

Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.

Research Excerpts

ExcerptRelevanceReference
"The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer."9.34Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. ( Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A, 2020)
"Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)."9.20Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015)
"To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)."9.19Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014)
"This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer."9.09UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."8.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age."7.91Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019)
"The aim of this report was to evaluate the onset of grade≥3 neutropenia during the first-cycle in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil and its relationship with clinical parameters of interest, such as overall survival (OS)."7.91The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. ( Bonetti, A; Giuliani, J, 2019)
"The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients."7.88Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018)
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)."7.88Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018)
"The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer."5.34Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. ( Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A, 2020)
"Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)."5.20Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015)
"To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)."5.19Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014)
"This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer."5.09UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."4.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102)."4.31Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. ( Fujii, H; Hirose, C; Hishida, S; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Suzuki, A; Tajima, JY; Takahashi, T; Watanabe, D, 2023)
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age."3.91Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019)
"The aim of this report was to evaluate the onset of grade≥3 neutropenia during the first-cycle in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil and its relationship with clinical parameters of interest, such as overall survival (OS)."3.91The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. ( Bonetti, A; Giuliani, J, 2019)
"The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients."3.88Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018)
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)."3.88Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018)
"The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated."3.85Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2017)
"Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)."3.69Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997)
" Major adverse events were neutropenia, leukopenia, anemia, and nausea."2.82Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016)
"The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy."2.79Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014)
"Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)."2.74Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. ( Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009)
" Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps."2.71[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. ( Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004)
"Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)."2.70Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002)
" The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump."2.69A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. ( Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000)
"Neutropenia is the most common adverse event and an important factor impacting chemotherapy continuation."1.48Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. ( Aisu, N; Daibo, K; Hasegawa, S; Kajitani, R; Kiyomi, F; Komono, A; Matsumoto, Y; Munechika, T; Sakamoto, R; Yoshida, Y, 2018)
" Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95."1.43Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016)

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (6.45)18.2507
2000's8 (25.81)29.6817
2010's15 (48.39)24.3611
2020's6 (19.35)2.80

Authors

AuthorsStudies
Van Cutsem, E4
Hochster, H3
Shitara, K3
Mayer, R3
Ohtsu, A5
Falcone, A4
Yoshino, T5
Doi, T4
Ilson, DH3
Arkenau, HT3
George, B3
Benhadji, KA3
Makris, L4
Tabernero, J3
Shiroyama, M1
Fukuoka, S1
Masuishi, T2
Takashima, A1
Kumekawa, Y1
Kajiwara, T1
Yamazaki, K3
Shimada, Y2
Esaki, T2
Makiyama, A2
Moriwaki, T2
Watanabe, D1
Fujii, H1
Ohata, K1
Iihara, H1
Kobayashi, R1
Hirose, C1
Hishida, S1
Matsuoka, S1
Tajima, JY1
Kiyama, S1
Takahashi, T1
Suzuki, A1
Matsuhashi, N1
Kasi, PM1
Grothey, A1
Cleary, JM1
Mayer, RJ1
Shinozaki, E1
Nishina, T1
Garcia-Carbonero, R1
Komatsu, Y1
Baba, H1
Argilés, G1
Tsuji, A1
Sobrero, A1
Yamaguchi, K1
Peeters, M1
Muro, K2
Zaniboni, A1
Sugimoto, N1
Tsuji, Y1
Hochster, HS1
Tran, B1
Hamada, C1
Tanase, T1
Benedetti, F1
Yamashita, F1
Lenz, HJ1
Tsuchiya, T1
Kamohara, R1
Muraoka, M1
Nagayasu, T1
Saeki, S1
Takenoyama, M1
Suzuki, M2
Inada, K1
Tokunaga, S1
Hayashi, T1
Urabe, S1
Koga, T1
Akamine, S1
Sugio, K1
Kwakman, JJM1
Vink, G1
Vestjens, JH1
Beerepoot, LV1
de Groot, JW1
Jansen, RL1
Opdam, FL1
Boot, H1
Creemers, GJ1
van Rooijen, JM1
Los, M1
Vulink, AJE1
Schut, H1
van Meerten, E1
Baars, A1
Hamberg, P1
Kapiteijn, E1
Sommeijer, DW1
Punt, CJA1
Koopman, M1
Kimura, M4
Usami, E4
Iwai, M3
Teramachi, H3
Yoshimura, T4
Yasue, F1
Kawachi, S1
Mitsuoka, M1
Ikeda, Y1
Yoshida, Y1
Sakamoto, R1
Kajitani, R1
Munechika, T1
Matsumoto, Y1
Komono, A1
Aisu, N1
Daibo, K1
Kiyomi, F1
Hasegawa, S1
Kashiwabara, K1
Semba, H1
Fujii, S1
Tsumura, S1
Giuliani, J1
Bonetti, A1
Sunaga, T1
Suzuki, S1
Kogo, M1
Kurihara, T1
Kaji, S1
Koike, N1
Harada, N1
Kiuchi, Y1
Lee, KW1
Kim, YJ1
Lee, KH1
Han, SW1
Kim, TY2
Oh, DY1
Im, SA1
Bang, YJ1
Choi, IS1
Kim, JH1
Tsuburaya, A1
Yoshida, K1
Kobayashi, M1
Yoshino, S1
Takahashi, M1
Takiguchi, N1
Tanabe, K1
Takahashi, N1
Imamura, H1
Tatsumoto, N1
Hara, A1
Nishikawa, K1
Fukushima, R1
Nozaki, I1
Kojima, H1
Miyashita, Y1
Oba, K1
Buyse, M1
Morita, S1
Sakamoto, J1
Mizushima, T1
Tamagawa, H1
Matsuda, C1
Murata, K1
Fukunaga, M1
Ota, H1
Hasegawa, J1
Tsujie, M1
Fukuzaki, T1
Hata, T1
Takemasa, I1
Ikeda, M1
Yamamoto, H1
Sekimoto, M1
Nezu, R1
Doki, Y1
Mori, M1
Kojima, T1
Bando, H1
Yamazaki, T1
Naito, Y1
Mukai, H1
Fuse, N1
Goto, K1
Ito, Y1
Go, M1
Ito, D1
Asano, H1
Hamauchi, S1
Kito, Y1
Komori, A1
Tsushima, T1
Narita, Y1
Todaka, A1
Ishihara, M1
Yokota, T1
Tanaka, T1
Machida, N1
Kadowaki, S1
Fukutomi, A1
Ura, T1
Onozawa, Y1
Ando, M1
Tajika, M1
Yasui, H1
Mori, K1
Taniguchi, H1
Surmont, V1
Aerts, JG1
Pouw, E1
Tan, KY1
Vernhout, R1
Gras, J1
Salomé, J1
Pronk, T1
Schmitz, PI1
Hoogsteden, H1
van Klaveren, RJ1
Bin, Q1
Li, J1
Liao, C1
Cao, Y1
Gao, F1
Rothenberg, ML1
Benedetti, JK1
Macdonald, JS1
Seay, TE1
Neubauer, MA1
George, CS1
Tanaka, MS1
Giguere, JK1
Pruitt, BT1
Abbruzzese, JL1
Nakamori, S1
Tujie, M1
Takahashi, Y1
Maruhashi, S1
Miyamoto, A1
Nagano, H1
Dono, K1
Umeshita, K1
Sakon, M1
Monden, M1
Ishida, H1
Akita, H1
Watanabe, Y1
Nakaguchi, K1
Kabuto, T1
Iwamoto, S1
Yoshioka, K1
Rivera, F1
Vega-Villegas, ME1
López-Brea, MF1
García-Castaño, A1
de Juan, A1
Ramos, FJ1
Collado, A1
Galdós, P1
Rubio, A1
del Valle, A1
Rama, J1
Mayorga, M1
Sanz-Ortiz, J1
Martin, M1
Casado, A1
López-Martin, JA1
Rodriguez-Lescure, A1
Nieto, Y1
Ayala, F1
Diaz-Rubio, E2
González-Larriba, JL1
Garcia Carbonero, I1
Sastre Valera, J1
Perez Segura, P1
Childs, HA1
Spencer, SA1
Raben, D1
Bonner, JA1
Newsome, J1
Robert, F1
Gregory, RK1
Johnston, SR1
Smith, IE1
Miles, D1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies[NCT01607957]Phase 3800 participants (Actual)Interventional2012-06-17Completed
A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552]Phase 30 participants (Actual)Interventional2016-03-31Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival

Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)

Interventionmonths (Median)
TAS-1027.1
Placebo5.3

Progression-free Survival

Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)

Interventionmonths (Median)
TAS-1022.0
Placebo1.7

Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs. (NCT01607957)
Timeframe: From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier

,
Interventionpercentage of participants (Number)
Any adverse event (AE)Any treatment-related AEAny ≥Grade 3 AEAny treatment-related ≥Grade 3 AEAny serious AE (SAE)Any AE resulting in discontinuationAny AE with outcome of death
Placebo93.254.751.79.833.613.611.3
TAS-10298.385.769.449.029.610.33.2

Reviews

1 review available for uracil and Neutropenia

ArticleYear
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2011, Volume: 13, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans

2011

Trials

14 trials available for uracil and Neutropenia

ArticleYear
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H

2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H

2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H

2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H

2022
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:1

    Topics: Colorectal Neoplasms; Drug Combinations; Humans; Japan; Neutropenia; Pyrrolidines; Thymine; Trifluri

2020
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    BMC cancer, 2020, Dec-04, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Non-Small-Cell Lung;

2020
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deo

2014
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2014
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
    Oncology, 2015, Volume: 89, Issue:3

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2015
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
    Cancer science, 2016, Volume: 107, Issue:5

    Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross-

2016
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Lung cancer (Amsterdam, Netherlands), 2009, Volume: 66, Issue:3

    Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small

2009
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D

2002
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; D

2004
Long term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in non-resectable locally advanced (stage IV-B) squamous
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Car

2007
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C

1997
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2000, Jul-01, Volume: 47, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia

2000
UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:10 Suppl 9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2000

Other Studies

16 other studies available for uracil and Neutropenia

ArticleYear
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
    Scientific reports, 2023, 10-20, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin

2023
Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.
    BMC cancer, 2023, Nov-08, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations

2023
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:1

    Topics: Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine; U

2020
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    International journal of clinical oncology, 2018, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2018
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
    Die Pharmazie, 2017, Jan-10, Volume: 72, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2017
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
    Die Pharmazie, 2018, 03-05, Volume: 73, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans;

2018
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.
    Anticancer research, 2018, Volume: 38, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival;

2018
Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy.
    Cancer investigation, 2018, Volume: 36, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L

2018
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
    Anticancer research, 2019, Volume: 39, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co

2019
The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.
    Anticancer research, 2019, Volume: 39, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Hum

2019
The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
    European journal of cancer care, 2014, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother

2014
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
    Die Pharmazie, 2016, Volume: 71, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female;

2016
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Fema

2017
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop

2006
[24 hour infusion of CPT-11/oral UFT/LV].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2006
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea

1997